| Item Type | Name |
|
Concept
|
Urinary Bladder, Overactive
|
|
Academic Article
|
Pathophysiology of the overactive bladder.
|
|
Academic Article
|
Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.
|
|
Academic Article
|
Conservative therapy for overactive bladder: pelvic floor exercises.
|
|
Academic Article
|
Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study.
|
|
Academic Article
|
Elevating our therapeutic expectations in overactive bladder.
|
|
Academic Article
|
Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review.
|
|
Academic Article
|
Disruptive effects of overactive bladder and urge urinary incontinence in younger women.
|
|
Academic Article
|
The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial.
|
|
Academic Article
|
Diagnosis of interstitial cystitis/ painful bladder syndrome in patients with overactive bladder symptoms.
|
|
Academic Article
|
Detrusor overactivity and urge urinary incontinence following trans obturator versus midurethral slings.
|
|
Academic Article
|
Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
|
|
Academic Article
|
Botulinum toxin A in the overactive bladder: current status and future directions.
|
|
Academic Article
|
A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women.
|
|
Academic Article
|
Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
|
|
Academic Article
|
Extended-release trospium chloride improves quality of life in overactive bladder.
|
|
Academic Article
|
Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin.
|
|
Academic Article
|
Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials.
|
|
Academic Article
|
Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
|
|
Academic Article
|
Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study.
|
|
Academic Article
|
Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference.
|
|
Academic Article
|
Long-term safety, tolerability and efficacy of fesoterodine in subjects with overactive bladder symptoms stratified by age: pooled analysis of two open-label extension studies.
|
|
Academic Article
|
Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study.
|
|
Academic Article
|
Predictors of persistent detrusor overactivity after transvaginal sling procedures.
|
|
Academic Article
|
The evolution of transdermal therapy for overactive bladder.
|
|
Academic Article
|
Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms.
|
|
Academic Article
|
Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms.
|
|
Academic Article
|
Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome.
|
|
Academic Article
|
Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged = 75 years) with overactive bladder syndrome.
|
|
Academic Article
|
Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB.
|
|
Academic Article
|
Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
|
|
Academic Article
|
Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial.
|
|
Academic Article
|
Subjective measures of efficacy and quality of life in overactive bladder syndrome.
|
|
Academic Article
|
Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin.
|
|
Academic Article
|
Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome.
|
|
Academic Article
|
Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: Post hoc analysis of pooled data from two randomized, placebo-controlled trials.
|
|
Academic Article
|
Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.
|
|
Academic Article
|
Reviewing the ICS 2002 terminology report: the ongoing debate.
|
|
Academic Article
|
Efficacy and tolerability of fesoterodine in women with overactive bladder.
|
|
Academic Article
|
Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement?
|
|
Academic Article
|
Oxybutynin: past, present, and future.
|
|
Academic Article
|
OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial.
|
|
Academic Article
|
Diagnosis and treatment of overactive bladder.
|
|
Academic Article
|
Vesico-ureteral reflux in women with idiopathic high-pressure detrusor overactivity: prevalence, bladder function, and effect on the upper urinary tract.
|
|
Academic Article
|
Durable improvements in urinary incontinence and positive treatment response in patients with idiopathic overactive bladder syndrome following long-term onabotulinumtoxinA treatment: Final results of 3.5-year study.
|
|
Academic Article
|
Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study.
|
|
Academic Article
|
OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial.
|
|
Academic Article
|
Does physician specialty affect persistence to pharmacotherapy among patients with overactive bladder syndrome?
|
|
Academic Article
|
Is There a Relationship Between Patient-Reported Satisfaction and Persistence on Overactive Bladder Syndrome Pharmacotherapy?
|
|
Academic Article
|
Subjective and objective responses to PTNS and predictors for success: a retrospective cohort study of percutaneous tibial nerve stimulation for overactive bladder.
|
|
Academic Article
|
Predictors of successful percutaneous tibial nerve stimulation (PTNS) in the treatment of overactive bladder syndrome.
|
|
Academic Article
|
Feasibility of a Fully Implanted, Nickel Sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence.
|
|
Academic Article
|
A Prospective Study to Evaluate Efficacy Using the Nuro Percutaneous Tibial Neuromodulation System in Drug-Naïve Patients With Overactive Bladder Syndrome.
|
|
Academic Article
|
Cognitive changes in women starting anticholinergic medications for overactive bladder: a prospective study.
|
|
Academic Article
|
Twelve-month Durability of a Fully-implanted, Nickel-sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence: A Single-Arm, Prospective Study.
|